Dr. Jed Rose is the President and CEO of the Rose Research Center.
He is also Director of the Duke Center for Smoking Cessation and a Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center. Dr. Jed Rose began work in the area of tobacco addiction research as a NIMH Postdoctoral fellow at the University of California at Los Angeles. A main focus of his research program has been the elucidation of the role of sensorimotor cues and the CNS effects of nicotine in reinforcing cigarette smoking behavior. He is co-inventor of the nicotine skin patch and other treatments for smoking cessation. His primary research goals are to elucidate the biological mechanisms underlying tobacco addiction and to promote the development of more effective treatments.
Rose is most known for co-inventing the nicotine skin patch with the late Murray Jarvik, M.D., Ph.D. and K. Daniel Rose in the early 1980s. Rose et al. published the first study of the pharmacokinetics of a transdermal nicotine patch in humans in 1984 and the subsequently filed US Patent 4920989 which was upheld in a priority decision in 1993. This work helped pave the way for the development of commercial nicotine skin patches.
Rose is also responsible for studying agonist-antagonist treatments that provided support for the development varenicline (Chantix).
Also in the 1980s, Rose developed novel methods for reaerosolizing selected constituents of tobacco smoke in cigarette-sized devices, a forerunner of modern e-cigarettes.
His first NIDA-funded grant, “Scaling the Reinforcing Value of Cigarette Smoke” (1981-2000), measured the role of nicotine in tobacco dependence, by selectively varying nicotine concentrations in smoke while holding tar yield constant, using a two-barreled smoke-mixing device. This method was employed in research cited in the 1988 U.S. Surgeon General’s Report on nicotine addiction.
Areas of Tobacco Research
- Nicotine Patch
- Inspiring the development of Chantix
- Sensory factors in tobacco addiction
- First radiotracer nicotine studies
- First adaptive treatment algorithm
Why should I participate?
Participants may gain access to new research treatments before they are widely available.
Additionally, participating leads to new drug discoveries, better treatment outcomes and ultimately can save countless lives. You may be among the first to benefit if the approach being studied is found to be helpful.